HC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Cadrenal Therapeutics (NASDAQ:CVKD) and maintained a price target of $3.
June 06, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Cadrenal Therapeutics and maintained a price target of $3, indicating continued confidence in the company's stock performance.
The reiteration of a Buy rating and maintenance of a $3 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and support the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100